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Diagnostic accuracy of the rapid urine
lipoarabinomannan test for pulmonary
tuberculosis among HIV-infected adults in
Ghana–findings from the DETECT HIV-TB study
Stephanie Bjerrum1,2*, Ernest Kenu3, Margaret Lartey3,4, Mercy Jemina Newman5, Kennedy Kwasi Addo6,
Aase Bengaard Andersen1 and Isik Somuncu Johansen1
Abstract
Background: Rapid diagnostic tests are urgently needed to mitigate HIV-associated tuberculosis (TB) mortality. We
evaluated diagnostic accuracy of the rapid urine lipoarabinomannan (LAM) test for pulmonary TB and assessed the
effect of a two-sample strategy.
Methods: HIV-infected adults eligible for antiretroviral therapy were prospectively enrolled from Korle-Bu Teaching
Hospital in Ghana and followed for minimum 6 months. We applied the LAM test on urine collected as a spot and
early morning sample. Diagnostic accuracy was analysed for a microbiological TB reference standard based on
sputum culture and Gene Xpert MTB/RIF results and for a composite reference standard including clinical follow-up
data. Performance of sputum smear microscopy was included for comparison.
Results: Of 469 patients investigated for TB, the LAM test correctly identified 24/55 (44 %) of microbiologically
confirmed TB cases. Sensitivity of the LAM test was positively associated with hospitalisation (67 %), Modified Early
Warning Score > 4 (57 %) and subsequent death (71 %). LAM test specificity was 95 % increasing to 98 % for the
composite reference standard. A two-sample LAM test strategy did not improve test performance. Using concentrated
sputum for Ziehl-Neelsen and fluorescence microscopy in combination yielded a sensitivity of 31/55 (56 %) that
increased to 35/55 (64 %) when the LAM test was added. Surprisingly, nontuberculous mycobacteria were cultured in
34/469 (7 %) and associated with a positive LAM test (p = 0.008).
Conclusions: LAM test sensitivity was highest in patients with poor prognosis and subsequent death and did not
increase with a two-sample strategy. A rigorous sputum microscopy strategy had superior sensitivity, but the simplicity
of the LAM test holds operational possibilities as a TB screening method among severely sick patients.
Keywords: Tuberculosis, HIV, Lipoarabinomannan, Urine, Diagnosis, Africa, Ghana
Background
Tuberculosis (TB) is the leading cause of death among
HIV-infected individuals initiating antiretroviral therapy
(ART) in sub-Saharan Africa [1]. Undiagnosed TB re-
mains highly prevalent in this population as identified in
studies of intensified TB screening pre-ART [2–4]; the
highest TB diagnostic yield achieved by microbiological
screening of all HIV-infected individuals regardless of
presenting symptoms [5]. While culture based diagnos-
tics remain the gold standard for TB diagnosis, it is
time-consuming and unavailable in many TB endemic
settings. The fully automated GeneXpert®MTB/RIF
(“Xpert”) assay can provide diagnosis within 2 hours, but
wide implementation of this assay is impeded by high
costs and requirements for electricity and maintenance
[6, 7]. Often, TB diagnosis relies on symptom-based
screening, chest x-ray and sputum smear microscopy for
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Acid Fast Bacilli (AFB) although these tools have
demonstrated limited performance [3, 8–10]. Recently,
the DETERMINE TB-LAM Ag test (“LAM test” Alere,
Waltham, MA, USA) was commercialised for point-of-
care TB diagnosis. It is a lateral flow immunochromato-
graphic strip test developed to detect the mycobacterial
lipoarabinomannan (LAM) antigen released from meta-
bolically active or degrading mycobacteria [11]. It can be
applied directly on urine and provides a result within
30 minutes. Previous LAM performance studies have
reported great variation in test sensitivity and specificity
[12–19]. A consensus paper on the LAM test highlights
issues with its performance and appropriate target group
and calls for further evaluations of the LAM test in
diverse settings [20].
We undertook a prospective study in Ghana to evaluate
the diagnostic accuracy of the LAM test to diagnose pul-
monary TB among HIV-infected individuals eligible for
ART. We assessed a two-sample strategy, similar to what
is conventionally applied for sputum microscopy, and ex-
plored the trade-off between the increase in sensitivity
against reduction in specificity when using the LAM test
as an add-on test to sputum smear microscopy.
Methods
Design
This is a cross sectional diagnostic accuracy study with a
longitudinal follow-up of minimum 6 months.
Study setting and population
As part of the DETECT HIV-TB study, participants were
recruited prospectively between January 2013 and March
2014 from the out- and inpatient departments, Fevers
Unit, Korle-Bu Teaching Hospital; Ghana’s largest public
hospital situated in the capital city Accra. The Fevers
Unit provides ART services including adherence coun-
selling, medical care and laboratory services for HIV-
infected individuals. The overall HIV-epidemic in Ghana
is moderate with a prevalence of 1.4 % in the general
population [21]. In 2013, the TB Control Programme in
Ghana conducted a national TB prevalence survey that
found an overall adult TB prevalence of 356/100,000
(personal communication with the programme manager
for the National TB Control Programme, Ghana, unpub-
lished data). This is much higher than the WHO estimated
prevalence of 71/100,000 and questions the estimated case
detection rates of 88 %, which is likely to be an overesti-
mation [22].
HIV-infected adults were consecutively enrolled into
the study if ≥18 years and eligible for lifelong ART, i.e.
severe and advanced HIV clinical disease (WHO clinical
stage 3 or 4 disease), a blood CD4 cell count ≤350 cells/
μl or pregnant [23, 24]. Patients on antituberculous
treatment of more than 2 days within the last 3 months
before enrolment or who were unable to produce
sputum or urine samples were excluded. Presence of
TB related symptoms was not used as inclusion or
exclusion criteria.
We used a standardized questionnaire to record demo-
graphic and clinical details including vital measures,
height and weight, TB specific signs and symptoms in-
cluding the WHO symptom screen with presence of more
than one of the following symptoms: cough, fever, weight
loss or night sweats [25] and previous history of TB. We
calculated the Modified Early Warning Score (MEWS) for
each participant as an indicator for illness severity. MEWS
is a scoring system based on the level of deranged physio-
logical parameters including systolic blood pressure, pulse
rate, respiratory rate, body temperature and level of con-
sciousness. A cut-off score > 4 has been considered pre-
dictive of poor outcomes [26]. Blood CD4 cell count was
obtained for participants at enrolment. Full blood count
and x-ray interpretation was obtained if available through
routine laboratory investigations.
At enrolment, participants were requested to provide a
spot urine specimen for LAM testing and one respira-
tory specimen for sputum smear microscopy, mycobac-
terial culture and Xpert assay. Participants were further
asked to deliver an early morning urine and sputum
sample within 7 days after enrolment. Medical records
were reviewed from time of enrolment to a minimum of
6 months post-enrolment. If medical records were un-
available, an interview with the participant or relatives of
the participant was conducted by phone. The following
were recorded: vital status, lost to follow-up, transfer
out, start on antituberculous treatment.
Ethics
Informed consent was obtained in writing from each par-
ticipant prior to enrolment in the study. The study proto-
col was approved by the Ethical and Protocol Review
Committee, University of Ghana Medical School (MS-Et./
M.4–P 3.3/2012-13) and evaluated by the Developing
Country Committee of the Danish National Committee
on Health Research Ethics (No. 1302133/1206169). Urine
LAM test results were not used for treatment decision-
making, but sputum microscopy, culture and Xpert results
were communicated to the responsible clinicians.
We followed the Standards for the Reporting of Diag-
nostic accuracy studies (STARD) criteria [27]. Additional
file 1 displays the STARD checklist (For more on STARD
see http://www.stard-statement.org/).
Urine sample analysis
Urine samples were transported to the Department of
Medical Microbiology within Korle-Bu Teaching Hos-
pital premises where study staff applied the LAM test on
fresh urine in accordance with the manufacturer’s
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instructions. A 60 μL of unprocessed urine was applied
to the sample pad at the bottom of the test strip. The
test result was read between 25–35 minutes later and
graded by comparing the test strip with a reference card.
We used the original 2012 reference scale card that con-
sisted of 5 colour intensity grades. The test band was
graded as zero if no visual band appeared and graded 1
through 5 for a visualized band of equal intensity as
those on the reference card. If a faint band was observed
with intensity lower than the grade 1 cut-point it was re-
corded as “faint”. Additional file 2 provides a figure of
the reference card used and its interpretation. Each test
was graded by two individual readers blinded to their
counterpart’s observations and to the patient identity
through the use of anonymous study ID’s. Reference
standard results were not known at the time of LAM
testing.
Sputum sample analysis
Sputum samples were analysed at the Reference TB
Laboratory at Noguchi Memorial Institute for Medical
Research or the TB laboratory at Korle-Bu Teaching
Hospital. Samples were processed according to standard-
ized protocols for mycobacterial microscopy and culture
by trained laboratory technicians [28, 29]. Sputum sam-
ples were decontaminated with N-acetyl-L-cysteine and
sodium hydroxide. Smears of centrifuged sputum sedi-
ment were examined microscopically and graded for
AFB using both Ziehl-Neelsen (ZN) staining method
and fluorescence microscopy of auramine O stained
smears. After re-suspension in phosphate buffer the spu-
tum sediment was cultured for mycobacteria using both
solid Lowenstein-Jensen medium and the BACTEC
mycobacteria growth indicator tube (MGIT) 960 system
(BD Diagnostics, Sparks, MD, USA) and incubated for
up to 8 and 6 weeks respectively. Positive cultures were
re-assessed for AFBs using ZN smear microscopy and an
anti-MPB64 antibody assay was used on AFB positive
cultures to confirm presence of M. tuberculosis. The
GeneXpert MTB-RIF assay was performed on either
fresh sputum sample or on sputum sediment according
to the manufacturer’s specifications (Cepheid, CA, USA)
after it became available at the Chest Clinic TB labora-
tory to also confirm TB.
Diagnostic classification for analysis
We defined a positive LAM test result as a test band with
intensity equal to or greater than the grade 2 cut-point
[14]. The first reading of the first sample was considered
the study result and used for all data analysis except for
analysis of inter-reader agreement and accuracy of a
two-sample strategy.
In the absence of a single suitable reference stand-
ard for TB diagnosis in a population of severely
immunocompromised HIV-infected individuals we used
the following composite TB case definition to categorize
participants:
“Confirmed TB” if M. tuberculosis culture positive or
Xpert positive in any of the sputum samples.
“Possible TB” if no positive culture or Xpert results
for TB, but one of the following; sputum smear
microscopy positive i.e. smears graded as scanty, 1+,
2+, and 3+; a clinical-radiological picture highly
suggestive of TB and started on antituberculous
treatment within two months; a clinical diagnosis of
active TB by a non-study clinician and started on
treatment within two months; death within two
months of enrolment reported to be due to TB per
medical record.
“Non–TB” if not meeting criteria for “Confirmed” or
“Possible” TB. Participants with growth of
nontuberculous mycobacteria (NTM) and no positive
cultures or Xpert results for M. tuberculosis were
assigned to this group.
Statistical analysis
Descriptive analysis was used to characterize the study
population and reported with interquartile range (IQR)
and standard deviations (SD) as appropriate. Kappa
statistics were used to determine inter-reader agreement
between LAM test results and agreement between test
results reported with the standard error (SE). Accuracy
measures (sensitivity, specificity, positive predictive values
(PPV), negative predictive values (NPV) and likelihood ra-
tio (LR)) were calculated with 95 % Confidence Interval
(CI). In our primary analysis, we used a microbiological
reference standard comparing “Confirmed TB” vs. partici-
pants with no positive cultures or positive Xpert results.
In the secondary analysis we used a composite reference
standard for TB and combined “Confirmed TB” and “Pos-
sible TB” for calculation of sensitivities versus “Non TB”
cases to calculate specificity. Figure 1 outlines the analysis
of groups. For subgroup analysis we stratified participants
by: enrolment site (hospitalised patients vs. outpatients);
CD4 cell count (CD4 < 100 cells/mm3 vs. CD4 ≥ 100
cells/mm3); MEWS (MEWS > 4 vs. MEWS ≤ 4); and
vital status at 2 months (dead vs. alive). Sensitivity and
specificity was compared across strata using chi-square
test or Fisher Exact test as appropriate. We determined
diagnostic accuracy for LAM test in combinations with
sputum smear microscopy and for the two-sample LAM
test strategy. When assessing performance of a combin-
ation of tests, the result was considered positive if any of
the tests were positive. The result was considered negative
if both tests were negative. McNemar’s test was used to
compare two different test sensitivities and specificities.
The cumulative probabilities of death were estimated by
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means of the Kaplain-Meier method, compared according
to LAM test results with the log-rank test. Statistical sig-
nificance was defined as a two-sided p-value less than 0.05
and all analysis were conducted using STATA™ version
13.1 software.
Results
Participants
In the study period, 571 HIV-infected adults were
screened and 469 were eligible according to our inclu-
sion criteria (Fig. 1). In total, 399 (85 %) were enrolled
from the outpatient clinic and 70 (15 %) were hospita-
lised patients (Table 1). Participants produced a mean of
1.8 (SD 0.36) urine samples with two urine samples
obtained from 396 (84 %) participants. Two sputum
samples were collected from 371 (79 %) participants
with a mean of 1.8 (SD 0.41) per participant.
TB was confirmed bacteriologically in 55 cases (preva-
lence 11.7 %; 95 % CI 9.1-15.0) and additional 45 cases
were defined as “Possible TB” (prevalence 9.6 %; 95 % CI
7.2-12.6). Sputum microscopy for AFB was positive in
31/55 (56 %) of “Confirmed TB” cases. Among the 45
“Possible TB” cases, 6/45 (13 %) were categorised as
“Possible TB” based on a positive sputum microscopy
for AFB, 25/45 (56 %) based on start-up of antitubercu-
lous treatment within 2 months, and 14/45 (31 %) died
within 2 months of follow-up with TB stated as the
cause of death.
Urine LAM test performance
All LAM tests provided a valid result with visible control
bar. The distribution of LAM test results across band in-
tensity grades was: no band, 194 (41 %); faint band, 168
(36 %); grade 1, 62 (13 %); grade 2, 10 (2 %); grade 3, 10
(2 %); grade 4, 16 (4 %) and grade 5, 9 (2 %). Inter-rater
agreement between the readers as to presence versus ab-
sence of a LAM test band with intensity of grade 2 cut-
point was 99.1 % (kappa 0.94; SE 0.05). Agreement as to
Fig. 1 Flowchart of study participants and analysis. *Of 29 participants excluded; three (3) were on antituberculous treatment; twenty one
(21) had no sputum samples; and five (5) had no urine sample. The remaining 469 participants were eligible for analysis with at least 1
sputum and 1 urine sample available
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test band grade was 69.2 % (kappa 0.54; SE 0.03) mainly
due to inter-rater variability between recording of grade
1 cut-point intensity vs. faint. Additional file 3a + b
details the inter-rater variability.
Analysis 1–Microbiological reference standard
For grade 2 cut-point positivity threshold the urine LAM
test had an overall diagnostic sensitivity of 44 % (95 % CI;
30–58) and specificity of 95 % (95 % CI; 92–97) using the
microbiological reference standard (Table 2). Additional
file 4 provides a table with the diagnostic accuracy of the
LAM test by all grade cut-point. Additional file 5 displays
the Receiver Operator Characteristic (ROC) curve for the
LAM test. In the subgroup analysis (Table 3), LAM test
sensitivity increased significantly among hospitalised pa-
tients (p = 0.035), participants with MEWS > 4 (p = 0.008)
and in participants who died within 2 months of follow-up
(p = 0.013). The increase in sensitivity among participants
with low CD4 did not reach statistically significance. The
inverse pattern was seen for test specificity being signifi-
cantly lower among strata with higher degree of diseases
severity or death as outcome.
Analysis 2–Composite reference standard for TB
When using the composite reference standard for
TB, the overall LAM test specificity increased to
Table 2 Overall performance of LAM test for diagnosis of tuberculosis
Total Sensitivity Specificity LR (+) LR (−) PPV NPV
N % (95 % CI) N % (95 % CI) (95 % CI) (95 % CI) % (95 % CI) % (95 % CI)
LAM test overall
Microbiological reference standard* 469 24/55 44 (30–58) 393/414 95 (92–97) 8.6 (5.1-14.4) 0.6 (0.5-0.8) 53 (38–68) 93 (90–95)
Composite reference standard** 469 36/100 36 (27–46) 360/369 98 (95–99) 14.8 (7.4-29.6) 0.7 (0.6-0.8) 80 (65–90) 85 (81–88)
*Primary analysis using a microbiological reference standard:” Confirmed TB” cases versus culture and Xpert negative cases
**Secondary analysis using a composite reference standard: “Confirmed TB” and “Possible TB” combined for calculations of sensitivity versus “Non TB”
LR (+) = Positive Likelihood Ratio, LR (−) = Negative Likelihood Ratio, PPV = Positive Predictive Value, NPV = Negative Predictive Value
Table 1 Characteristics of study population
All Confirmed TB Possible TB Non-TB
n = 469 n = 55 n = 45 n = 369
Enrolment site
Out patients 399 (85 %) 40 (73 %) 20 (44 %) 339 (92 %)
In patients 70 (15 %) 15 (27 %) 25 (56 %) 30 (8 %)
Median Age in years (IQR) 38 (31–45) 37 (29–44) 37 (33–41) 38 (32–45)
Female 301 (64 %) 24 (44 %) 29 (64 %) 241 (65 %)
Median CD4 (IQR)* 127 (35–256) 92 (41–176) 46 (12–176) 142 (41–282)
CD4 < 100 195 (43 %) 29 (55 %) 28 (65 %) 138 (39 %)
CD4 > =100 259 (57 %) 24 (45 %) 15 (35 %) 220 (61 %)
Mean MEWS (SD) 3 (1.95) 5 (2.20) 4 (2.37) 3 (1.59)
MEWS > 4 101 (22 %) 35 (63 %) 19 (42 %) 47 (13 %)
MEWS < = 4 368 (78 %) 20 (36 %) 26 (58 %) 322 (87 %)
Median HGB g/dl** (IQR) 9.7 (8.1-11.2) 8.2 (6.2-9.6) 8.0 (6–10) 10 (9–12)
Median BMI (IQR) 20 (18–22) 18 (16–19) 19 (16–21) 21 (18–23)
TB suspects, WHO symptom screen 426 (91 %) 53 (96 %) 43 (96 %) 330 (90 %)
Current Cough 222 (48) 42 (76 %) 28 (62 %) 152 (41 %)
Fever 238 (52 %) 45 (82 %) 28 (62 %) 165 (45 %)
Weight loss 390 (83 %) 51 (93 %) 39 (87 %) 300 (81 %)
Night Sweats 161 (34 %) 26 (49 %) 16 (36 %) 119 (32 %)
Previous history of TB 28 (6 %) 4 (7 %) 2 (4 %) 22 (6 %)
Overall mortality*** 81 (17 %) 18 (33 %) 23 (51 %) 40 (11 %)
*CD4 count missing for 15 participants
**HGB missing for 39 participants
***80 participants were lost to follow-up at 6 months and 11 transferred out
IQR = Interquartile range, SD = Standard Deviation
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98 % (95 % CI; 95–99), but sensitivity reduced to
36 % (95 % CI; 27–46) (Table 2). Sensitivity increased for
the strata with poor outcome, while specificity remained
above 94 % for all strata (Table 3).
LAM test performance with a two-sample strategy using
the microbiological reference standard
Of all participants, 396/469 (84 %) was able to deliver
two urine samples for LAM test. Among these, the
LAM test correctly identified 14/40 (35 %) of the
“Confirmed TB” cases in the first sample tested and
additionally 2 “Confirmed TB” cases 16/40 (40 %) when
including positive LAM test results from the second
sample. The additional two cases both had a grade 1
band intensity at the first LAM test. The increase in
sensitivity was not statistically significant (35 % vs. 40 %;
p = 0.5) and specificity dropped significantly from 96 %
to 92 % (p < 0.001) when the second LAM test was ap-
plied. The LAM test was positive in 40/458 (9 %) of the
spot samples and 45/407 (11 %) of the early morning
samples. Agreement between spot and morning LAM
test results was 95.5 % (kappa 0.72; SE 0.05). Additional
file 6a + b detail the inter-variability between spot and
morning samples. Sensitivity of urine LAM test performed
on a spot sample was 40 % (21/52; 95 % CI: 27–55)
slightly lower than when applied on an early morning
urine samples with a sensitivity of 42 % (18/43; 95 %
CI: 27–58). Specificity was 95 % (387/406; 95 % CI:
93–97) and 93 % (337/364; 95 % CI: 89–95) for spot
and morning sample respectively.
Sputum smear microscopy performance alone and in
combination with LAM test using the microbiological
reference standard
ZN microscopy detected 29/55 (53 %) of the confirmed
TB cases and ZN + fluorescence microscopy in combin-
ation detected 31/55 (56 %) (Table 4). Concordance be-
tween LAM test and microscopy was moderate both for
ZN microscopy alone (91.4 %; kappa 0.45; SE 0.05) and
ZN + fluorescence microscopy (91.4 % kappa 0.47; SE
0.05). Similar to the LAM test accuracy, the sensitivity
of sputum microscopy increased in subgroups with poor
prognosis (data not shown). Combining LAM test to ZN
and fluorescence microscopy maximised sensitivity to
35/55 (64 %) non-significantly higher than for the ZN
and fluorescence microscopy alone. There were four
additional TB cases detected by adding the LAM test; all
had CD4 < 100 cells/mm3 and two of them subsequently
died. The LAM false positive cases were 26 of whom 17
(65 %) were defined as “possible TB”.
LAM test cross reactivity with nontuberculous
mycobacteria
NTM was cultured in sputum from 34 (prevalence
7.2 %; 95 % CI 5.2-10.0) participants and additionally
two participants were co-infected with NTM and TB. The
LAM test was positive in 5/34 (15 %, 95 % CI; 5–31) par-
ticipants with a positive LR+ of 1.6 (95 % CI; 0.7-3.8).
Compared to those without any mycobacteria, a positive
NTM culture was associated with a positive LAM test
(4 % vs. 15 %; p = 0.008).
Table 3 The overall sensitivity and specificity of the LAM test and stratified by subpopulation
LAM test overall Total Microbiological reference standard Composite reference standard
Sensitivity Specificity Sensitivity Specificity
N % (95 % CI) p-value N % (95 % CI) p-value N % (95 % CI) p-value N % (95 % CI) p-value
469 24/55 44 (30–58) 393/414 95 (92–97) 36/100 36 (27–46) 360/369 98 (95–99)
By Department 469
Inpatient 70 10/15 67 (38–88) 47/55 86 (73–94) 17/40 43 (27–59) 29/30 97 (83–100)
Out patient 399 14/40 35 (21–52) 0.035 346/359 96 (94–98) 0.001 19/60 32 (20–45) 0.269 331/339 98 (95–99) 0.74
By CD4 strata* 454
CD4 < 100 195 14/29 48 (29–68) 148/166 89 (83–93) 24/57 42 (29–56) 130/138 94 (89–98)
CD4 > = 100 259 8/24 33 (16–55) 0.272 233/235 99 (97–100) <0.001 9/39 23 (11–39) 0.054 219/220 100 (98–100) 0.002
By MEWS 469
MEWS > 4 101 20/35 57 (39–74) 54/66 82 (70–90) 29/54 54 (40–67) 44/47 94 (83–99)
MEWS < = 4 368 4/20 20 (6–44) 0.008 339/348 97 (95–99) <0.001 7/46 15 (6–29) <0.001 316/322 98 (96–99) 0.061
By Vital status
at 60 days**
397
Dead 52 10/14 71 (42–92) 33/38 87 (72–96) 14/29 48 (29–68) 22/23 96 (78–100)
Alive 345 11/34 32 (17–51) 0.013 302/311 97 (95–99) <0.001 14/58 24 (14–37) 0.023 281/287 98 (96–99) 0.483
*15 participants with missing values for CD4 were excluded from analysis
**63 participants were lost to follow-up at 2 months and 7 transferred out
MEWS =Modified Early Warning Score
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Mortality
During the study 81 (17 %) of the participants died after
a median of 25 days from enrolment. The 6-month mor-
tality was 73 (16 %), 80 (17 %) participants were lost to
follow-up (LTFU) and 11 (2 %) transferred out. Con-
firmed TB patients had a 2-month mortality of 14/55
(25 %) and at 6-month 18 (33 %) cases had died, 7 cases
(13 %) were LTFU and 1 (4 %) transferred out. LAM
positive participants had a significantly higher probability of
death compared to LAM negative in the overall population
(p < 0.001) (Fig. 2a) and among “confirmed TB” (p = 0.002)
(Fig. 2b). LTFU among LAM positive participants was not
significantly higher than among LAM negative (6/45; 18 %
vs. 74/424; 13 %, p = 0.5). In a sensitivity analysis assuming
that all participants LTFU had died, the probability of
death remained significantly higher for LAM-positive
than LAM-negative participants overall (p < 0.001) and
among confirmed TB cases (p = 0.044).
Discussion
We evaluated the urine LAM strip test for TB diagnosis
among ART eligible adults in Ghana where TB is
reported as the most common AIDS defining event and
cause of death [30]. We found that rapid urine LAM test
could identify 44 % of confirmed TB cases with a specifi-
city of 95 % and that a two-sample strategy for the LAM
test did not improve sensitivity. The LAM test was easily
performed and had a high inter-reader reliability. Sensi-
tivity increased to 67 % among hospitalised patients and
was associated with death and high clinical illness score
(MEWS > 4); further, we found a tendency of increased
sensitivity among patients with lower CD4 cell counts.
Our findings affirm that sensitivity of the LAM test is
highest for the sickest patients and those holding the
greatest risk of dying. This is consistent with findings by
Lawn et al. who found increased LAM test sensitivity
among patients with CD4 cell count < 100 cells/mm3,
CRP > 200 mg/L, severe anaemia (<8.0 g/dL), advanced
symptoms and subsequent death [31, 32]. To our know-
ledge, four other studies have evaluated urine LAM test
among HIV-infected individuals irrespective of the pres-
ence of TB symptoms [12–15] and four other studies
among HIV-infected TB suspects [16–19]. The lowest over-
all LAM test sensitivity of 25 % as reported by Balcha et al.
Fig. 2 Cumulative probability of survival. a Shown for the full study population (n = 469) by LAM test status. b Shown for confirmed TB cases (n = 55)
by LAM test status
Table 4 Sensitivity and specificity of the LAM test, sputum smear microscopy and combinations of the tests
Total Sensitivity Specificity LR (+) LR (−) PPV NPV
N % (95 % CI) N % (95 % CI) % (95 % CI) % (95 % CI) % (95 % CI) % (95 % CI)
LAM test 469 24/55 44 (30–58) 393/414 95 (92–97) 8.6 (5.1-14.4) 0.6 (0.5-0.8) 53 (38–68) 93 (90–95)
ZN microscopy 467 29/55 53 (39–66) 406/412a 99 (97–100) 36.2 (15.7-83.3) 0.5 (0.4-0.6) 83 (66–93) 94 (91–96)
ZN + Fluorescence microscopy 467 31/55 56 (42–70) 406/412a 99 (97–100) 38.7 (16.9-88.5) 0.4 (0.3-0.6) 84 (68–94) 94 (92–96)
LAM + ZN microscopy 469 34/55 62 (48–75)a 388/414 94 (90–96)a,b 9.8 (6.4-15.1) 0.4 (0.3-06) 57 (43–69) 95 (92–97)
LAM + ZN + Fluorescence Microscopy 469 35/55 64 (50–76)a 388/414 94 (91–96)a,c 10.1 (6.6-15.5) 0.4 (0.3-0.6) 57 (44–70) 95 (93–97)
For combinations of test a positive result was recorded if any of the tests were positive
ap < 0.05 for comparison with LAM test alone
bp < 0.05 for comparison with ZN microscopy alone
cp < 0.05 for comparison with ZN + Fluorescence microscopy
LR (+) = Positive Likelihood Ratio, LR (−) = Negative Likelihood Ratio, PPV = Positive Predictive Value, NPV = Negative Predictive Value, ZN = Ziehl Neelsen
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in a study that included HIV-infected individuals with
CD4 < 350 regardless of TB symptoms [12]. The highest
sensitivity of 50 % was reported for grade 2 cut-point in a
study among hospitalised TB suspects [18]. LAM test sen-
sitivity was consistently the highest among hospitalised
populations and strata with lower CD4 cell count, suggest-
ing that critically ill patients are the appropriate target
group for LAM testing. No study has previously reported
a correlation with MEWS although this could be a simple
and objective alternative to identify the target group for
LAM testing. MEWS was originally developed to detect
critically ill patients at risk of catastrophic deterioration in
high-income countries [26], but has since gained a wider
application in medical wards and intensive care units to
predict hospital admission and mortality also in resource
limited settings [33, 34]. A great advantage of MEWS is
that it is based on simple measures that are routinely col-
lected as part of most clinical consultations. Our finding
of a significantly higher risk of death for LAM-positive
compared with LAM-negative TB patients further empha-
sises that the LAM test identify TB patients with the
greatest clinical need.
Specificity of the LAM test is paramount for utility of
LAM as a screening test. We found considerably lower
specificity among subgroups with signs of critical illness
or subsequent death than the target of 95 % for new
point-of-care tests for TB diagnosis [35]. Using the com-
posite reference standard, however, increased overall
specificity to 98 % and to 94 % in all subgroups with
poor outcome. This probably reflects the well-known
limitations of sputum culture and Xpert to detect TB
among severely sick HIV-infected individuals. We sought
to optimize our microbiological reference standard by per-
forming two sputum cultures on both solid and liquid
media, and by adding Xpert results. Despite these efforts,
the microbiological reference standard leads to underesti-
mation of specificity. This is similar to findings by Peter et
al. where LAM test specificity increased from 78 % to
94 % when the composite reference standard was used
instead of a microbiological reference standard [18]. An-
other key factor for test specificity is the positivity thresh-
old for the LAM test as shown in previous studies [13, 16,
18]. There is consensus of using grade 2 cut-point as posi-
tivity threshold and in 2014 the LAM test manufacturers
changed the reference scale card omitting the band corre-
sponding to grade 1. However, we report a large number
of tests with band-intensity fainter than the original grade
2 cut-point as did another prospective LAM study [16]. It
is important to acknowledge that such visible bands, al-
though fainter than the positivity threshold, in a clinical
setting could prompt clinicians to interpret the LAM test
as positive and lead to over treatment.
LAM is also a component of the NTM cell wall [36],
but the possibility of NTM causing false positive LAM
test results has been sparsely addressed. In a cohort of
cystic fibrosis patients we previously reported that 2/23
(8.7 %) of NTM infected patients were LAM-positive at
a grade 2 cut-point increasing to 9/23 (39.1 %) for grade
1 cut-point [37]. In the context of HIV infected individ-
uals, 10 NTM culture positive cases have previously
been described to be LAM positive [15, 38–40]. We
found a positive LAM test for 5/34 (15 %) of NTM cul-
ture positives. The prevalence of NTM culture positive
was high in our study and associated with a positive
LAM test. While this raises concern that NTM among
HIV infected individuals affect LAM test specificity, its
importance needs to be evaluated in studies applying
appropriate case definitions for NTM disease.
A two-sample test strategy including an early morning
sample has not been evaluated to date for the LAM test.
We found that an additional sample did not increase
overall performance of the LAM test and agreement be-
tween results for a spot and morning sample was high.
A recent study explored a two-test strategy performed
on the same sample and did not show any added diag-
nostic value of the second test [13].
Previous studies found that the LAM test sensitivity
was superior to sputum smear microscopy and found
incremental diagnostic value of combining the two tests
[12, 16, 19]. We found higher sputum smear micros-
copy sensitivity that contrasts other studies comparing
microscopy with the LAM test. This could be due to our
use of sputum concentration and fluorescence microscopy
both known to increase diagnostic sensitivity [41, 42], and
collection of two samples for the majority of participants.
A similar and rigorous sputum sampling and microscopy
methodology is not always achievable in a routine clinical
setting and the LAM test could be preferred for reasons
other than a higher diagnostic accuracy alone.
The LAM test is simple to perform at the bedside and
collection of urine is simple and poses minimal biohazard;
all attractive features in settings with overburdened TB la-
boratories. Urine based diagnosis further holds a potential
to improve TB diagnosis in children with one study of
LAM test showing reasonable sensitivity in HIV-positive
TB infected children [43]. A number of other biomarkers
have been detected at increased levels in the urine from
patients with active TB [44, 45]. LAM remains among the
most promising so far, but is limited by its modest sensi-
tivity and use among HIV-infected individuals only.
The strengths of this study are prospective data collec-
tion, LAM testing on fresh urine and a minimum of
6 months’ follow-up. We chose to enrol HIV-infected indi-
viduals initiating ART regardless of clinical presentation as
this target group has been identified as a particularly vul-
nerable group for prevalent and undiagnosed TB. We had
several limitations with regard to our reference standard
that did not include Xpert results for all participants or
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investigation of extrapulmonary samples that could have
increased specificity further, especially among those with
more advanced immunodeficiency. Moreover, we did not
have capacity to perform sputum induction to improved
sputum sample quality. Despite active follow-up through
personal calls to participants and their relatives the LTFU
was high, but comparable to several other African HIV-
cohort studies [46]. Mortality is a frequent cause of LTFU
[47, 48] and mortality rates in our study could have been
higher had we performed a more thorough follow-up with
e.g. house-visit. However, sensitivity analysis assuming that
all participants LTFU had died did not change the associ-
ation between LAM-positivity and mortality.
Conclusions
Despite modest sensitivity, we found that the LAM test
has a potential to improve TB case detection when ap-
plied as a screening test among the sickest patients and
those at the greatest risk of dying, especially in settings
without easy access to high quality microscopy, culture
or more advanced diagnostic technologies. A two-sample
strategy did not improve test performance.
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